Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lubiprostone in Opioid-induced Bowel Dysfunction
NCT00595946Phase 3Completed
- Sponsor
- Sucampo
- Start
- Aug 2007
- Primary completion
- Mar 2009
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced bowel dysfunction (OIBD) comparing Lubiprostone with Placebo (2 arms). Primary endpoint: Mean Weekly Spontaneous Bowel Movements at 8 weeks. Started Aug 2007; status: completed.
02
Drugs
cobiprostone
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on NCT00595946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595946.